StockIQ.techGlaukos Corporation (GKOS) Stock Analysis
Free AI-powered analysis and research for Glaukos Corporation stock
Sector: Healthcare
GKOS snapshot
Data as of 3 Nov 2026 close. Updated daily.
Glaukos Corporation scores 76/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 93% of its 52-week range, up 171.6% over the past year. Latest reported figures show a profit margin of -24.6%, return on equity of -22.8% and revenue growth of +58.0%.
What is driving the score
- RSI Very High (81): -5
- Strong Uptrend: +12
- MACD Bullish: +8
- Strong Revenue Growth (58.0%): +8
- Unprofitable (-24.6%): -15
- Low Debt (0.15 D/E): +8
- Strong Liquidity (4.57 Current Ratio): +8
- Negative ROE (-22.8%): -10
- High P/B (19.60): -5
- Strong Long-term Uptrend: +8
- Very Strong Rise (+171.6% over 1 year): +12
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full GKOS report
Glaukos Corporation (GKOS) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze GKOS Now →📰 Latest Update
Glaukos (GKOS) Earnings, Outlook ‘Brighter’; Shares Soar to All-Time High
Fri, October 30, 2026 at 1:58 AM UTC 3 min read
Glaukos (GKOS) reported strong earnings, leading to a significant surge in its stock price, which reached an all-time high. The positive outlook reflects the company's robust performance and growth potential in the ophthalmic medical technology sector. This development is crucial for investors, as it indicates increasing market confidence and the potential for continued financial success.